Enhancement of the anti-tumor activity of therapeutic monoclonal antibodies by CXCR4 antagonists

  title={Enhancement of the anti-tumor activity of therapeutic monoclonal antibodies by CXCR4 antagonists},
  author={Yanping Hu and M. Gale and J. Shields and Carrie Garron and M. Swistak and T. Nguyen and G. Jacques and Robert Fogle and W. Siders and J. Kaplan},
  journal={Leukemia \& Lymphoma},
  pages={130 - 138}
Abstract The interaction between CXCR4 on the surface of tumor cells and CXCL12 in the stroma is believed to contribute to tumor cell survival and protection against drug treatment. Inhibition of stromal survival signals by CXCR4 antagonists has been reported to render tumor cells more sensitive to chemotherapy, but little is known about potential synergy with monoclonal antibodies. In this study, administration of the small molecule CXCR4 antagonists plerixafor and GENZ-644494 was found to… Expand
Anti-CCR7 therapy exerts a potent anti-tumor activity in a xenograft model of human mantle cell lymphoma
The potential of heparanase as a therapeutic target in cancer.
The CXCR4 antagonist plerixafor enhances the effect of rituximab in diffuse large B-cell lymphoma cell lines
Dual blockade of CXCL12‐CXCR4 and PD‐1–PD‐L1 pathways prolongs survival of ovarian tumor–bearing mice by prevention of immunosuppression in the tumor microenvironment
  • Yang Zeng, Binghao Li, +9 authors M. Poznansky
  • Medicine
  • FASEB journal : official publication of the Federation of American Societies for Experimental Biology
  • 2019
Homeostatic chemokines guide lymphoma cells to tumor growth-promoting niches within secondary lymphoid organs
Lymphoma: Immune Evasion Strategies
The yin and the yang of follicular lymphoma cell niches: role of microenvironment heterogeneity and plasticity.


Inhibition of CXCR4 with the novel RCP168 peptide overcomes stroma-mediated chemoresistance in chronic and acute leukemias
Translating an Antagonist of Chemokine Receptor CXCR4: From Bench to Bedside
Neutrophils contribute to the biological antitumor activity of rituximab in a non-Hodgkin's lymphoma severe combined immunodeficiency mouse model.
Pharmacology of AMD3465: a small molecule antagonist of the chemokine receptor CXCR4.